TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 786773

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (M)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study: 30898819

Group type: EXPERIMENTAL
Intervention: Multimodal neuronavigation-guided precision bypass
Number of subjects: 100

Group type: COMPARATOR
Intervention: Empirical bypass
Number of subjects: 100
Study: 28646935

Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL) procedure
Number of subjects: 206

Group type: COMPARATOR
Intervention: Blinded sham control
Number of subjects: 206
Study: 25126957

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg daily for 40 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21971959

Group type: EXPERIMENTAL
Intervention: Early stage cervical and endometrial cancer treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Benign gynaecological conditions (n = 60)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pre-invasive cancer patients (n = 52)
Number of subjects: 53
Study: 21272198

Group type: EXPERIMENTAL
Intervention: Physicians with a higher percentage of patients with hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physicians with a higher number of total clinic visits per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physicians with inpatient duties
Number of subjects: 0
Study: 19427219

Group type: EXPERIMENTAL
Intervention: Frequency of 0.33 Hz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Frequency of 0.66 Hz
Number of subjects: 15

Group type: COMPARATOR
Intervention: Frequency of 0.33 Hz and 0.66 Hz
Number of subjects: 15
Study: 16990976

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (20 IU injection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Glyceryl trinitrate ointment (300 mg of 0.2% applied three times daily for 30 days)
Number of subjects: 30
Study: 12821497

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coadministration of valacyclovir and cephalexin
Number of subjects: 0
Study: 10848841

Group type: EXPERIMENTAL
Intervention: Plasma viscosity
Number of subjects: 964

Group type: COMPARATOR
Intervention: Plasma viscosity (top quintile)
Number of subjects: 964
Study: 8633687

Group type: EXPERIMENTAL
Intervention: Divalproex, 750 mg/day for 2 days, then 1,000 mg/day on days 3-5, adjusted as clinically indicated for 21 days
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Divalproex, serum levels >= 125 micrograms/ml
Number of subjects: 65
Study: 1538042

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (Trental) 400 milligram tablets three times daily
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 6234271

Group type: EXPERIMENTAL
Intervention: Norfloxacin for 7 days
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Norfloxacin for 3 days
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 758

Group type: COMPARATOR
Intervention: Cotrimoxazole for 7 days
Number of subjects: 758

Group type: COMPARATOR
Intervention: Amoxycillin
Number of subjects: 758

Group type: COMPARATOR
Intervention: Citrated nalidixic acid for 3 days
Number of subjects: 758
Study: 30130437

Group type: EXPERIMENTAL
Intervention: Adult BVM with different grips (3 grips: 3 fingers, 2 fingers, 1 finger)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pediatric BVM with different grips (3 grips: 3 fingers, 2 fingers, 1 finger)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pediatric BVM
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pediatric BVM vs Adult BVM
Number of subjects: 50
Study: 31337169

Group type: EXPERIMENTAL
Intervention: Curved-needle blocking group (CB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Straight-needle blocking group (SB)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Straight needle no-blocking group (SN)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Curved-needle no-blocking group (CN)
Number of subjects: 88
Study: 29100704

Group type: EXPERIMENTAL
Intervention: Optimal pre-dilation (balloon to core laboratory-derived reference vessel diameter ratio ≥1:1)
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: Vessel size selection (reference vessel diameter ≥2.25 mm and ≤3.75 mm)
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: Post-dilation (with a noncompliant balloon at ≥18 atm and larger than the nominal scaffold diameter, but not by >0.5 mm larger)
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: BVS implantation in properly sized vessels
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: Aggressive pre-dilation
Number of subjects: 2973

Group type: EXPERIMENTAL
Intervention: Optimal post-dilation
Number of subjects: 2973
Study: 26495054

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 43
Study: 23504617

Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard prophylaxis
Number of subjects: 63
Study: 21881569

Group type: EXPERIMENTAL
Intervention: Spironolactone (400 mg)
Number of subjects: 64
Study: 18810239

Group type: EXPERIMENTAL
Intervention: Baseline serum urate levels (measured in mg/dl)
Number of subjects: 15183
Study: 16410646

Group type: EXPERIMENTAL
Intervention: Healthy pregnancy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Gestational hypertension
Number of subjects: 182
Study: 12627066

Group type: EXPERIMENTAL
Intervention: Maze III surgery combined with mitral valve surgery (n=25)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mitral valve surgery without Maze III (n=10)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 11777142

Group type: EXPERIMENTAL
Intervention: Adhesive retention tape (Mefix)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alginate (Kaltostat)
Number of subjects: 30
Study: 9033440

Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg nocte (B20)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bambuterol 10 mg nocte (B10)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Terbutaline 3 mg t.i.d. (T)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo solution (P)
Number of subjects: 84
Study: 8509565

Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg once daily, n = 93)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo (n = 100)
Number of subjects: 193
Study: 3549837

Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 27.5 mug/kg per 10 min, maintenance: 0.375 mug/kg per min)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 50 mug/kg per 10 min, maintenance: 0.50 mug/kg per min)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 75 mug/kg per 10 min, maintenance: 0.75 mug/kg per min)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Milrinone (loading: 50 mug/kg per 10 min, maintenance: 0.25 mug/kg per min)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Milrinone (all doses)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Milrinone (high dose)
Number of subjects: 189
Study: 31594294

Group type: EXPERIMENTAL
Intervention: Phototherapy device (mUV/VIS and infrared light)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo device (no light emission)
Number of subjects: 0
Study: 29188481

Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (no case management intervention)
Number of subjects: 250
Study: 26845539

Group type: EXPERIMENTAL
Intervention: Nonablative fractional erbium laser 1,340 nm
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Microneedling
Number of subjects: 46
Study: 23832756

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 181

Group type: COMPARATOR
Intervention: No Training
Number of subjects: 181
Study: 23449874

Group type: EXPERIMENTAL
Intervention: Probiotic Streptococcus salivarius strain M18
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20678799

Group type: EXPERIMENTAL
Intervention: Monthly intravitreal injections of 0.5 mg ranibizumab
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 3 monthly injections followed by dosing as needed (PRN)
Number of subjects: 30
Study: 18271973

Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 7
Study: 16556673

Group type: EXPERIMENTAL
Intervention: 200 microg IN buserelin every day (group C)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 200 microg IN buserelin twice a day (group D)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 200 microg IN buserelin three times a day (group E)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 10,000 IU hCG followed by vaginal administration of micronized progesterone (3x 200 mg/day) (group A)
Number of subjects: 23
Study: 12672279

Group type: EXPERIMENTAL
Intervention: BCNU wafers
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo wafers
Number of subjects: 240
Study: 10902992

Group type: EXPERIMENTAL
Intervention: E = 1171 kJ + 12 mg iron
Number of subjects: 55

Group type: COMPARATOR
Intervention: S = 104 kJ
Number of subjects: 55

Group type: COMPARATOR
Intervention: M = 12 mg iron + 209 kJ
Number of subjects: 55
Study: 9365036

Group type: EXPERIMENTAL
Intervention: HGV RT‐PCR positive post-transplant in 8 of 11 fulminant patients
Number of subjects: 14

Group type: COMPARATOR
Intervention: HGV RT‐PCR positive in 5 of 21 control liver transplant recipients
Number of subjects: 14
Study: 8263313

Group type: EXPERIMENTAL
Intervention: 12.5 mg venlafaxine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 25 mg venlafaxine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 mg venlafaxine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3032828

Group type: EXPERIMENTAL
Intervention: Dietary fibre supplement of 7.3 g per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31429603

Group type: EXPERIMENTAL
Intervention: Patients with asthma and diabetes (n=unknown)
Number of subjects: 2431

Group type: COMPARATOR
Intervention: Patients with only diabetes (n=unknown)
Number of subjects: 2431

Group type: EXPERIMENTAL
Intervention: Asthmatic and diabetic patients using budesonide (up to 825 mcg)
Number of subjects: 2431
Study: 29753161

Group type: EXPERIMENTAL
Intervention: INSPIRE online program (immediate access)
Number of subjects: 451
Study: 27022068

Group type: EXPERIMENTAL
Intervention: Epirubicin/cyclophosphamide-docetaxel (EC-Doc)
Number of subjects: 459

Group type: COMPARATOR
Intervention: 5-fluoruracil/epirubicin/cyclophosphamide (FEC)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Continuous genomic grade index (GGI)
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Immunohistochemical subtyping (IHC4)
Number of subjects: 459
Study: 24654699

Group type: EXPERIMENTAL
Intervention: Phaco-trabeculectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phacoemulsification alone
Number of subjects: 60
Study: 22350703

Group type: EXPERIMENTAL
Intervention: 50 mg rectal diclofenac (reduced to 25 mg for patients weighing <50 kg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (saline infusion without diclofenac)
Number of subjects: 104
Study: 16023511

Group type: EXPERIMENTAL
Intervention: MIT therapy
Number of subjects: 748

Group type: COMPARATOR
Intervention: No MIT therapy
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Prayer
Number of subjects: 748

Group type: COMPARATOR
Intervention: No prayer
Number of subjects: 748
Study: 12481892

Group type: EXPERIMENTAL
Intervention: Amifostine (AMI) 910 mg/m2 in 15 min infusion preceding MEL 200 mg/m2
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no AMI)
Number of subjects: 10
Study: 9637805

Group type: EXPERIMENTAL
Intervention: Rectal diazepam gel (0.2 to 0.5 mg/kg based on age)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Rectal diazepam gel
Number of subjects: 125
Study: 8620677

Group type: EXPERIMENTAL
Intervention: Zileuton 600mg every 6 hours for 13 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zileuton with digoxin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo with digoxin
Number of subjects: 12
Study: 2577474

Group type: EXPERIMENTAL
Intervention: Somatostatin-14
Number of subjects: 7
Study: 334206

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine 15 mg
Number of subjects: 0
Study: 31629348

Group type: EXPERIMENTAL
Intervention: CES-HGel (carbohydrate-electrolyte solution with sodium alginate and pectin)
Number of subjects: 9

Group type: COMPARATOR
Intervention: CES-Std (standard carbohydrate-electrolyte solution)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CES-HGel
Number of subjects: 9

Group type: COMPARATOR
Intervention: CES-Std
Number of subjects: 9
Study: 30222805

Group type: EXPERIMENTAL
Intervention: Ranibizumab plus deferred laser (0.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocinolone acetonide (FAc) 0.2 μg/day
Number of subjects: 0
Study: 26525313

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care without bupivacaine
Number of subjects: 140
Study: 25509435

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 47

Group type: COMPARATOR
Intervention: Reduced spino-epidural anesthesia
Number of subjects: 47
Study: 22990933

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN), n=20
Number of subjects: 35

Group type: COMPARATOR
Intervention: Parenteral nutrition (control), n=15
Number of subjects: 35
Study: 19859788

Group type: EXPERIMENTAL
Intervention: Cognitive behavior group therapy (CBT)
Number of subjects: 30
Study: 18333863

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV; 1200 mg t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg q.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r; 400 mg/100 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted saquinavir (SQV/r; 1000 mg/100 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose ritonavir (RTV; 100 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atazanavir (ATZ; 400 mg q.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATZ/r; 300 mg/100 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted tipranavir (TPV/r; 500 mg/200 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maraviroc (100 mg b.i.d.)
Number of subjects: 0
Study: 16203030

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling according to an intensified minimal intervention strategy
Number of subjects: 392

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study: 12401633

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 1.5 mg/kg with epinephrine 5 microg/mL
Number of subjects: 24

Group type: COMPARATOR
Intervention: Epidural ropivacaine 1.5 mg/kg without epinephrine (plain group)
Number of subjects: 24
Study: 10621575

Group type: EXPERIMENTAL
Intervention: Long-term income support, long-term work-search waivers, and on-call advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capital infusions and up-front classes
Number of subjects: 0
Study: 7546757

Group type: EXPERIMENTAL
Intervention: C6 stellate ganglion nerve block with radiocontrast and local anesthetic (5 ml increments to 20 ml total volume)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C7 stellate ganglion nerve block with radiocontrast and local anesthetic (5 ml increments to 20 ml total volume)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: C6 stellate ganglion nerve block
Number of subjects: 10
Study: 2360541

Group type: EXPERIMENTAL
Intervention: 4.0 mg pyridoxine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5 mg pyridoxine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 25 mg zinc
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 mg zinc
Number of subjects: 40
Study: 343182

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional practices (amniotomy and intravenous oxytocin infusion or oral prostaglandin therapy)
Number of subjects: 0
Study: 31282092

Group type: EXPERIMENTAL
Intervention: Couple-based cognitive behavioural intervention (CBI)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Women-alone CBI
Number of subjects: 388

Group type: COMPARATOR
Intervention: Control (standard perinatal care)
Number of subjects: 388
Study: 30959753

Group type: EXPERIMENTAL
Intervention: Cooked Brassica carinata leaves
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Raw Brassica carinata leaves
Number of subjects: 22

Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 22
Study: 27908604

Group type: EXPERIMENTAL
Intervention: Phospholipid liposomal spray (Tears Again®) applied to one eye four times daily for two weeks.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control eye (no treatment).
Number of subjects: 31
Study: 26104939

Group type: EXPERIMENTAL
Intervention: RT plus total androgen suppression (TAS)
Number of subjects: 1979

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 1979
Study: 23915015

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10 sessions
Number of subjects: 251

Group type: COMPARATOR
Intervention: Sertraline (SER) - 50-200 mg/d
Number of subjects: 251

Group type: COMPARATOR
Intervention: Both groups received diabetes treatment as usual
Number of subjects: 251

Group type: COMPARATOR
Intervention: Hamilton Depression Rating Scale (HAMD)
Number of subjects: 251
Study: 21995387

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 3360

Group type: COMPARATOR
Intervention: Control (standard adjuvant systemic therapy without zoledronic acid)
Number of subjects: 3360
Study: 19187370

Group type: EXPERIMENTAL
Intervention: 100 mg mifepristone
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: 24-hour interval to misoprostol administration
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: 48-hour interval to misoprostol administration
Number of subjects: 2181

Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 2181
Study: 17083172

Group type: EXPERIMENTAL
Intervention: Condition NN (sports wheelchair on a tartan surface)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Condition RN (increased mechanical resistance)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Condition RD (limited turning capacity)
Number of subjects: 11
Study: 15186939

Group type: EXPERIMENTAL
Intervention: Ivermectin at 800 microg/kg given at 3-monthly intervals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ivermectin at 150 microg/kg given annually
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin at high doses (800 microg/kg)
Number of subjects: 0
Study: 11302289

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8mg or 16mg
Number of subjects: 185

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5mg
Number of subjects: 185
Study: 9453273

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15 mg
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lorazepam 1.25 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 7876396

Group type: EXPERIMENTAL
Intervention: 500 mg oral dose of metronidazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: 5 g of 0.75% metronidazole intravaginal gel (37.5 mg metronidazole)
Number of subjects: 12
Study: 3340942

Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 120
Study: 31356278

Group type: EXPERIMENTAL
Intervention: FOLFOX perioperative chemotherapy (4 cycles before surgery and 8 cycles after)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (6 months of adjuvant FOLFOX after colectomy)
Number of subjects: 120
Study: 29798778

Group type: EXPERIMENTAL
Intervention: O-SES (Sirolimus-Eluting Stent)
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES (Everolimus-Eluting Stent)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: O-SES
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: O-SES (in diabetic patients)
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES (in diabetic patients)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: O-SES (in small vessels)
Number of subjects: 452

Group type: COMPARATOR
Intervention: X-EES (in small vessels)
Number of subjects: 452
Study: 26780673

Group type: EXPERIMENTAL
Intervention: Individual schema therapy (ST)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Attention control condition (exploration phase)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No-treatment control condition (baseline phase)
Number of subjects: 25
Study: 25710460

Group type: EXPERIMENTAL
Intervention: 24,25(OH)2D3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study: 23099196

Group type: EXPERIMENTAL
Intervention: Cellulose (CE) membranes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Polymethylacrylate (PMMA) membranes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy volunteers (CON)
Number of subjects: 21
Study: 20812121

Group type: EXPERIMENTAL
Intervention: Cumulative probability information on Chlamydia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single incident probability information on Chlamydia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cumulative probability information on HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single incident probability information on HIV
Number of subjects: 0